Lasmiditan

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Lasmiditan，也称为 COL-144 和 LY573144，是一种新型、中枢作用、高选择性 5-HT(1F) 受体激动剂 (K1=2.21 μM)，无血管收缩活性，在证明中静脉输注时似乎有效。概念性偏头痛研究。

Lasmiditan, also known as COL-144 and LY573144, is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (K1=2.21 μM) without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. Lasmiditan showed efficacy in its primary endpoint, with a 2-hour placebo-subtracted headache response of 28.8%, though with frequent reports of dizziness, paresthesias, and vertigo.

——

——

COL-144 | LY573144

Others

Other Targets

5-HT1F

Neurological Disease

——

439239-90-4

377.14

C19H18F3N3O2

>98% (HPLC)

——

CN1CCC(CC1)C(=O)c1nc(ccc1)NC(=O)c1c(cc(cc1F)F)F

——

(-20℃)

With Ice Pack

≥ 2 years